Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by jimsenioron Oct 10, 2022 1:03pm
135 Views
Post# 35015827

RE:RE:RE:RE:RE:RE:Biotech buyouts.

RE:RE:RE:RE:RE:RE:Biotech buyouts.
to Noteable, let me preface this by saying I do like reading your posts. Chacun a son gout.

Yes. Not in a buyout. But their best foot forward is we want at least Canada, and that  want complicates matters. Perhaps this is done in biotech; surely Pharma knows how to handle this sort of thing. They should just pass it on.

You did remind me of something I had been thinking about a while back. That is AN. They have broad rights to pelareorep. Perhaps they have a buyer for those rights. Not sure if they could just sell the rights. I do imagine if they got bought out the rights would go with.  Cheers

PS Does MC have rights that would be akin to an NSR in mining? TIA
<< Previous
Bullboard Posts
Next >>